Search Results 321-330 of 12292 for Multiple myeloma red flag

1. Novel Support Options In Autologous Stem Cell Transplant For Multiple Myeloma - Mayo Clinic

   ... multiple myeloma undergoing autologous stem cell transplantation? Participation eligibility. Participant eligibility includes age, gender, type and stage of ...

2. Dasatinib And Quercetin With CAR-T Therapy For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma - Mayo Clinic

   Dasatinib And Quercetin With CAR-T Therapy For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma ... multiple myeloma. Participation ...

3. A Study To Evaluate VSV-hIFNbeta-NIS To Treat Patients With Relapsed/Refractory Multiple Myleoma, Acute Myeloid Leukemia, Or T-cell Lymphoma - Mayo Clinic

   Multiple myeloma (MM) previously treated with an IMID, a proteosome inhibitor and an alkylating agent; OR. Acute myeloid leukemia (AML), excluding acute ...

4. A Study Of MT-0169 In Participants With Relapsed Or Refractory Multiple Myeloma Or Non-Hodgkin Lymphoma - Mayo Clinic

   It is planned that 39-60 patients with your disease condition (RR multiple myeloma) will take part in Part I, and approximately 54 patients will take part in ...

5. A Safety Study Of SGN-CD352A For Patients With Relapsed/Refractory Multiple Myeloma - Mayo Clinic

   SGN-CD352A will be given every 4 weeks to a small group of patients with multiple myeloma. Participation eligibility. Participant eligibility includes age ...

6. Ixazomib Plus Pomalidomide And Dexamethasone In Treating Patients With Relapsed Or Relapsed/Refractory Multiple Myeloma - Mayo Clinic

   Giving ixazomib with pomalidomide and dexamethasone may be an effective treatment for relapsed or relapsed/refractory multiple myeloma. Participation ...

7. Dose-Escalation Study Of Cevostamab (BFCR4350A) In Participants With Relapsed Or Refractory Multiple Myeloma (R/R MM) - Mayo Clinic

   Dose-Escalation Study Of Cevostamab (BFCR4350A) In Participants With Relapsed Or Refractory Multiple Myeloma (R/R MM). Print details. Share; Facebook · Twitter.

8. Clinical trials - Oncology (Medical)

   This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma.

9. Hematology - Clinical trials

   Inclusion Criteria are the following: age ≥ 18, blood cancer diagnosis (including B-ALL, multiple myeloma, and lymphoma), receiving a CAR-T product, able to ...

10. A Study To Evaluate 3 Dose Schedules Of Daratumumab In Participants With Smoldering Multiple Myeloma - Mayo Clinic

    The purpose of this study is to evaluate three different daratumumab dose schedules to treat participants who have Smoldering Multiple Myeloma. Participation ...